scholarly journals Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh

2015 ◽  
Vol 9 (4) ◽  
pp. e0003699 ◽  
Author(s):  
Emiliano Lucero ◽  
Simon M. Collin ◽  
Sujit Gomes ◽  
Fatima Akter ◽  
Asaduzzam Asad ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Line Treatment ◽  
First Line ◽  
Short Course ◽  
First Line Treatment

Short-course Regimens of Liposomal Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis in Children

2017 ◽  
Vol 36 (9) ◽  
pp. 849-854 ◽  
Author(s):  
Panagiotis Krepis ◽  
Ioanna Argyri ◽  
Adamantia Krepi ◽  
Areti Syrmou ◽  
Nikos Spyridis ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Short Course

scholarly journals Case Report: Post Kala-Azar Dermal Leishmaniasis with History of Visceral Leishmaniasis

2021 ◽  
Vol 8 (5) ◽  
pp. 69-72
Author(s):  
Pavankumar Narapaka ◽  
Kalpana Katikala
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
First Line ◽  
Treatment Regimens ◽  
First Line Therapy ◽  
Kala Azar ◽  
History Of

The complication of visceral leishmaniasis is post-kala-azar dermal leishmaniasis (PKDL). PKDL typically occurs as a result of treatment failure or parasite resistance to treatment regimens, as well as poor patient follow-up. In the treatment of visceral leishmaniasis and post-kala-azar dermal leishmaniasis, Liposomal Amphotericin B is considering as first-line therapy. We're going to show you a case where Liposomal Amphotericin B was used to treat it. Keywords: visceral leishmaniasis, post-kala-azar dermal leishmaniasis, PKDL, kala-azar

Successful Treatment of Antimony-Resistant Visceral Leishmaniasis with Liposomal Amphotericin B (L-AmpB-LRC) in a Child

1995 ◽  
Vol 25 (2) ◽  
pp. 80-81 ◽  
Author(s):  
S C Karande ◽  
K F John Boby ◽  
K R Lahiri ◽  
M K Jain ◽  
N A Kshirsagar ◽  
...  
Keyword(s):  
Case Report ◽  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
West Bengal ◽  
Liposomal Amphotericin B ◽  
First Line ◽  
Duration Of Treatment ◽  
Major Health Problem ◽  
Major Health

Visceral leishmaniasis continues to be a major health problem in Bihar and West Bengal states of India. In Bihar almost 44 million people in 28 districts and in West Bengal 5.5 million people in eight districts are at risk of visceral leishmaniasis1. Pentavalent antimonial (Sbv) compounds are the first-line drugs, and amphotericin B is used when failure to respond to antimony occurs2. We report the case of a 7-year-old boy with advanced antimony-resistant visceral leishmaniasis who was successfully treated by liposomal amphotericin B (L-AmpB-LRC) manufactured in our institute. This case report documents the efficacy of L-AmpB-LRC in such a patient and highlights the need for a longer duration of treatment.

scholarly journals Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)

1996 ◽  
Vol 22 (6) ◽  
pp. 938-943 ◽  
Author(s):  
R. N. Davidson ◽  
L. di Martino ◽  
L. Gradoni ◽  
R. Giacchino ◽  
G. B. Gaeta ◽  
...  
Keyword(s):  
Visceral Leishmaniasis ◽  
Amphotericin B ◽  
Liposomal Amphotericin ◽  
Liposomal Amphotericin B ◽  
Short Course
Sign in / Sign up

Export Citation Format

Share Document